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Abstract
Synthetic peptides are widely used in immunological research as epitopes to stimulate their cognate T cells. These
preparations are never completely pure, but trace contaminants are commonly revealed by mass spectrometry quality
controls. In an effort to characterize novel major histocompatibility complex (MHC) Class I-restricted b-cell epitopes in non-
obese diabetic (NOD) mice, we identified islet-infiltrating CD8+ T cells recognizing a contaminating peptide. The amount of
this contaminant was so small to be undetectable by direct mass spectrometry. Only after concentration by liquid
chromatography, we observed a mass peak corresponding to an immunodominant islet-specific glucose-6-phosphatase
catalytic subunit-related protein (IGRP)206-214 epitope described in the literature. Generation of CD8+ T-cell clones
recognizing IGRP206-214 using a novel method confirmed the identity of the contaminant, further underlining the
immunodominance of IGRP206-214. If left undetected, minute impurities in synthetic peptide preparations may thus give
spurious results.
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Introduction
Synthetic peptides produced by fluorenylmethyloxycarbonyl
(FMOC) chemistry are widely used in a variety of research
fields. In immunology, the main interest of peptides is that
they can be synthesized to reproduce the amino acid sequence
of antigenic epitopes, which are the protein fragments
recognized by T cells upon processing and presentation by
antigen-presenting cells (APCs). When tailored at an optimal
amino acid length, they do not require uptake and processing by
APCs, as they can directly bind major histocompatibility
complex (MHC) Class I (8–11 amino acid length) and Class II
(,12–20 amino acid length) molecules on the APC surface for
immediate presentation to CD8+ and CD4+ T cells, respec-
tively.
Another major attractiveness is that production of peptides in
suitable quantities and purity grades is much easier than that of
recombinant antigens, which frequently carry over small protein
or endotoxin contaminants from the bacterial, yeast or
baculovirus systems where they are generated [1]. Thus,
peptides are employed in different immunological studies both
in vitro, to stimulate epitope-specific T cells, and in vivo, as
immunizing agents in mice and as vaccination antigens in
human trials [2].
Similarly, peptides are largely used in type 1 diabetes research
to pinpoint the molecular targets of autoreactive T cells [3] which
ignite recognition and destruction of insulin-producing pancreatic
b cells [4]. Once identified, these epitopes are invaluable reagents
to track the corresponding T cells and to neutralize their
pathogenic potential through suitable tolerogenic delivery [5].
Despite these major advantages, even synthetic peptides cannot
be produced to complete purity. This can frequently lead to
misleading results, which are seldom reported in the literature
[6,7,8]. To minimize these drawbacks, the workflow of peptide
synthesis includes quality control steps, where purity is assessed
through high performance liquid chromatography (HPLC) and
mass spectrometry (MS) analyses before delivery to the final users.
These analyses are frequently useful a posteriori to troubleshoot
unexpected results, as contaminant peaks identified by MS can be
scrutinized more carefully.
In this report, we describe an instance of a peptide contaminant
which went undetected in several quality control MS analyses.
Nonetheless, this minute contaminant was capable of eliciting
peptide-specific T-cell responses in vitro. The troubleshooting
procedure demonstrating the involvement of such contaminant in
the observed results is described, including a novel technique to
select antigen-specific CD8+ T-cell clones from infiltrated islets of
non-obese diabetic (NOD) mice.
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Results
Identification of a MHC Class I-restricted candidate
epitope in NOD mice
We set up to investigate the kinetics of CD8+ T-cell IFN-c
responses to a selected panel of previously described b-cell epitopes
[9]. After isolating the islet infiltrates and culturing them for 7 d in
the presence of IL-2 to enrich the population of CD8+ T cells, we
observed that IFN-c responses were very weak vis a` vis most
peptides, except for 3 of them: IGRP206-214, PIB15-23 and PIA7-21
(Fig. 1A–B). As reported [10], responses to IGRP206-214 and its
mimotope NRP-V7 were detectable in NOD mice of different
ages, while PIB15-23-reactive T cells were only detected until 12
weeks (Fig. 1B).
While IGRP206-214 and PIB15-23 are well described Class I K
d-
restricted epitopes [11,12], PIA7-21 has been previously described
as a Class II-restricted epitope [13]. To confirm that the observed
PIA7-21-induced responses were Class I-restricted, we measured
IFN-c release upon peptide stimulation in both CD4+ and CD8+
T cells and found that only CD8+ T cells responded to PIA7-21
(Fig. 1C).
As the PIA7-21 peptide was unexpectedly long to bind to MHC
Class I registries, we hypothesized that there could be a shorter
variant either present in the peptide preparation or processed
during peptide pulsing. However, testing of potential 9–11-mer
core epitopes within the PIA7-21 sequence, either in spontaneous
islet infiltrates or in splenocytes following peptide immunization,
did not yield any similar IFN-c response (data not shown). Indeed,
we found two epitopes, PIA9-17 and PIA13-21, which showed
significant T-cell responses after peptide immunization, but no
spontaneous T-cell responses were observed in islet infiltrates
(Fig. 1C).
New peptide syntheses fail to reproduce the same
reactivity
The PIA7-21 peptide was resynthesized by another manufacturer
at two different purity grades (75.7% and 96.9%). Neither of these
new peptide preparations was capable of eliciting T-cell responses
similar to our previous synthesis (Fig. 2). We thus hypothesized
that the observed reactivity could be due to a contaminant present
in the first peptide preparation.
Figure 1. b-cell epitope-specific CD8+ T-cell IFN-c responses in NOD islet infiltrates. (A) Representative staining showing IFN-c responses
of spontaneous NOD islet-infiltrating CD8+ T cells recalled in vitro with different peptides. Percent cells present in each quadrant are given. (B) IFN-c-
producing CD8+ T-cell responses in islets from NOD mice of different ages (n = 4/group) following in vitro peptide stimulation. (C) PIA7-21-specific
responses in islet infiltrates originate from CD8+, but not from CD4+ T cells. The percent of IFN-c+ CD4+ and CD8+ T cells after in vitro peptide recall
(n = 4/group) is shown.
doi:10.1371/journal.pone.0028866.g001
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The original PIA7-21 preparation contains a PIB15-23
contaminant
A first MS analysis on the original PIA7-21 preparation
highlighted a 1009,51 m/z mass peak compatible with the MH+
adduct of the PIB15-23 peptide (Fig. 3A). However, this contam-
inant could not explain the observed T-cell responses since, as
shown in Fig. 1B, the PIB15-23 peptide does not induce T-cell
responses as strong as contaminated PIA7-21 and is not recognized
in islet infiltrates of older NOD mice. To definitely rule out the
involvement of PIB15-23, we used the contaminated PIA7-21
preparation to stimulate PIB15-23-specific splenocytes from G9C8
transgenic mice expressing a PIB15-23-specific T-cell receptor [14].
No response was observed (data not shown), suggesting that the
amount of PIB15-23 contaminant was insufficient to elicit T-cell
responses. Thus, we hypothesized that there could be another
peptide contaminating the original PIA7-21 preparation.
Fractionation of the original PIA7-21 preparation reveals a
mass peak corresponding to IGRP206-214 that elicits
IGRP206-214-specific T-cell responses
To concentrate other possible peptide contaminant(s), we used
HPLC fractionation. Ninety-six fractions were collected, concen-
trated 10-fold and subsequently tested for CD8+ T-cell IFN-c
responses from islet infiltrates. Only one of these 96 fractions was
able to elicit a T-cell response (Fig. 3B). This fraction was
reanalyzed by MS (Fig. 3C). The previously identified 1009.51 m/
z peak corresponding to PIB15-23 was again detected, along with a
1096.62 m/z peak not previously visualized in the unfractionated
PIA7-21 sample (compare with Fig. 3A). This peak is compatible
with the MH+ adduct of the IGRP206-214 peptide. One further MS
analysis attempted to conclusively identify IGRP206-214 but could
only sequence part of the peptide (VYLKTNVFL) (Fig. 4). This is
probably due to the extremely low amount of this contaminant.
To verify whether this minute IGRP206-214 peptide contaminant
was responsible for the observed T-cell responses, we performed a
parallel IFN-c/TMr staining. We stimulated cultured islet infiltrates
with the contaminated PIA7-21 preparation and double-stained them
for intracellular IFN-c and NRP-V7-loaded Kd TMrs (Fig. 5). The
same CD8+ T cells which secreted IFN-c in response to the
contaminated PIA7-21 preparation also bound the NRP-V7 TMr
(Fig. 5A), similar to IGRP206-214-stimulated cells (Fig. 5B). Staining
with a control TUM-loaded Kd TMr or stimulation with peptide
diluent alone did not yield any IFN-c/TMr double-positive
population (Fig. 5C–D). This experiment proves that the
IGRP206-214 contaminant present in our PIA7-21 peptide sample is
capable of eliciting IGRP206-214-specific CD8+ T-cell responses. We
can also exclude the presence of other contaminants capable of
stimulating CD8+ T cells, as ,90% of contaminant-stimulated
IFN-c+ cells were also NRP-V7 TMr+ (Fig. 5A).
CD8+ T-cell clones raised against the contaminated PIA7-21
peptide preparation are IGRP206-214- specific
To finally prove that IGRP206-214 was the contaminant inducing
T-cell responses, we expanded and cloned CD8+ T cells
responding to our contaminated peptide. A diagram of the cloning
procedure is shown in Fig. 6A. Total islet infiltrates were initially
stimulated and expanded using islets from NOD-RIPB7 mice as a
source of antigen. These islets further express the co-stimulatory
molecule B7.1 [15]. The expanded infiltrates were subsequently
challenged with the contaminated PIA7-21 preparation, stained
with the cytotoxic granule marker CD107a/b [16] and sorted
based on positive staining (Fig. 6B). Upon this peptide recall,
19.5% of islet-stimulated CD8+ T cells responded by CD107a/b
upregulation. This fraction was single-cell-sorted. After one further
round of stimulation with RIPB7 islets, 3 growing wells were
identified out of the 60 seeded (5.0%). These 3 clones were tested
for specificity by TMr staining (Fig. 6C). All of them stained
uniformly positive for the NRP-V7 Kd TMr, but not for the PIB15-
23 nor for the control TUM K
d TMr.
Discussion
When we set out to investigate islet-infiltrating CD8+ T-cell
responses to a panel of different b-cell peptides, we identified a
candidate Class I-restricted epitope derived from the insulin A
chain. New preparations of the same peptide did not however
elicit CD8+ T-cell responses, and MS analyses on concentrated
fractions revealed that the original preparation was contaminated
with an IGRP206-214 epitope that was responsible for the observed
responses. When validating epitope panels for T-cell recognition, it
is therefore important that strong responses measured against a
given peptide are reproduced on a separate preparation to rule out
these pitfalls.
This IGRP206-214 contaminant was introduced during peptide
synthesis and purification and not during laboratory manipulation.
Indeed, peptide sampling from different portions of the vial
including its very bottom gave similar T-cell responses, which
would not be the case if cross-contamination from an IGRP206-214
preparation occurred during weighing of the lyophilized powder.
Further supporting this conclusion, the original PIA7-21 prepara-
tion, although .90% pure, also contained traces of other peptides
originated from insulin (i.e. PIB15-23) that were detected by MS.
Impurities in synthetic peptides are mostly accounted for by
products of deletion, additional residue incorporation, truncation
and incomplete de-protection in solid phase synthesis [17]. This is
Figure 2. New PIA7-21 peptide syntheses fail to reproduce the
same CD8+ T-cell responses. IFN-c production by islet-infiltrating
CD8+ T cells following in vitro stimulation with 3 different preparations
of PIA7-21 peptide. The percent of IFN-c+CD8+ cells is given.
doi:10.1371/journal.pone.0028866.g002
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not the case for our findings, since peptide contaminants
corresponded to different amino acid sequences. Thus, the most
likely possibility is that the peptide preparation was contaminated
by improper handling of HPLC equipment during purification.
Insufficient washing steps may have left traces of other peptides
previously purified on the same column. Indeed, the manufactur-
er’s log records revealed that PIB15-23 and IGRP206-214 prepara-
tions were purified on the same day, by the same operator using
the same equipment.
The main interest of this case report is that the IGRP206-214
peptide contaminant remained undetected by conventional MS
analyses, and a compatible mass peak could finally be revealed
only by concentrating the sample 10-fold. This emphasizes the
exquisite sensitivity of T cells in sensing even minute amounts of
their cognate antigens. We used different technical approaches to
identify this contaminant. To conclusively prove that IGRP206-214
was eliciting CD8+ T-cell responses, we produced clones selected
based on upregulation of the cytotoxic granule marker CD107a/b
[16] following peptide exposure. This approach is attractive for
cloning epitope-specific CD8+ T cells for which the corresponding
TMrs are not available. Indeed, very few CD8+ T-cell clones
recognizing b-cell epitopes have been isolated from spontaneous
islet infiltrates in the NOD mouse [18,19,20].
Our results further emphasize the impressive immunodomi-
nance of the IGRP206-214 epitope within the NOD islet infiltrates.
They also exemplify how a fraction of IGRP206-214-specific CD8+
T cells infiltrating the islets is of very high avidity, as it was capable
of responding to minute amounts of peptide.
In conclusion, high purity peptides may hide traces of
contaminating peptides potentially leading to experimental pitfalls.
Functional T-cell assays are extremely sensitive to these impurities,
which may be missed by MS analysis. While this sensitivity makes
T-cell assays particularly vulnerable, it can also provide means to
conclusively identify these contaminants.
Figure 3. MS analysis of 3 different preparations of PIA7-21 peptide and nanochromatography fractionation of the contaminated
PIA7-21 batch. (A) MS analysis: a contaminant with a mass peak of 1009,516 compatible with the MH+ adduct of PIB15-23 is detected in the
contaminated PIA7-21 preparation. (B) One hundred microliters of a 50 mM solution of contaminated PIA7-21 peptide were subjected to
nanochromatography and separated in 96 fractions. Each of these fractions was tested for its ability to induce IFN-c responses in islet-infiltrating
CD8+ T cells. Results obtained with one single positive fraction compared with one of the remaining 95 negative fractions are shown. (C) The T-cell-
positive fraction identified was reanalyzed by MS. The obtained mass list shows two species at 1009,516 and 1096,619 m/z, compatible with the MH+
adduct of PIB15-23 and IGRP206-214, respectively.
doi:10.1371/journal.pone.0028866.g003
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Materials and Methods
Peptides
Proinsulin (PI)B24-C1 (FFYTPMSRRE), PIC15-30 (SFGDLQTL-
ALEVARQK), islet-specific glucose-6-phosphatase catalytic subunit-
related protein (IGRP)21-29 (TYYGFLNFM), glutamic acid
decarboxylase (GAD)206-220 (TYEIAPVFVLLEYVT), GAD247-266
(NMYAMLIARYKMFPEVKEKG), and GAD524-543 (SRLSKVA-
PVIKARMMEYGTT) were produced by Schafer-N. PIB24-C36
(FFYTPMSRREVED), PIC32-A12 (KRGIVDQCCTSICS) and
non-contaminated PIA7-21 peptides (CTSICSLYQLENYCN) were
produced by GL Biochem. All these peptides were .80% pure.
IGRP206-214 (VYLKTNVFL), PIB15-23 (LYLVCGERG), dystrophia
myotonica kinase (DMK)138-146 (FQDENYLYL) and contaminated
PIA7-21 (CTSICSLYQLENYCN) were produced by ‘‘manufacturer
X’’ at .90% purity.
Mice
NOD mice were bred and housed in specific pathogen-free
conditions. NOD mice were crossed with C57BL/6J-RIP-B7-1
mice [15] to obtain a first generation (F1) of offspring that was
used to prepare islet feeders [18]. G9C8 transgenic mice
expressing the T-cell receptor from a G9C8 CD8+ clone
recognizing the PIB15-23 peptide [14] were also used. All
experiments were conducted according to ethic guidelines. This
study was approved by the local ethics committee for animal
experimentation (Comite´ re´gional d’e´thique pour l’expe´rimentation animale,
approval number: P2.AL.116.09).
Figure 4. Partial sequencing of the IGRP206-214 contaminant by MS/MS. (A) MS analysis of the contaminated PIA7-21 preparation. (B) MS/MS
analysis of the 1096.34 m/z compatible with the MH+ adduct of IGRP206-214.
doi:10.1371/journal.pone.0028866.g004
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Preparation of pancreatic islet cell infiltrates
Mice were sacrificed and pancreatic islets isolated after
perfusion with 0.75 mg/ml collagenase P (Roche), as described
[21,22]. To measure antigen-specific CD8+ T-cell responses, islets
were isolated and cultured for 7 d in the presence of 50 U/ml
recombinant human interleukin (IL)-2 (R&D). Infiltrating cells
were then collected and analyzed.
Flow cytometry
Cells were stained with PE-labeled Kd tetramers (TMrs) synthe-
sized by the National Institute of Health Tetramer Core Facility and
loaded with NRP-V7 (a mimotope of the IGRP206-214 epitope;
KYNKANVFL) [11] and control TUM peptide (KYQAVTTTL).
Peptide-stimulated interferon (IFN)-c responses were measured using
intracellular IFN-c staining after incubation for 5 h in the presence of
10 mM peptide and 10 mg/ml Brefeldin A (Sigma). Phorbol myristate
acetate (PMA)/ionomycin (1 mg/ml/each) were used as a polyclonal
positive control stimulus. CD8-Alexa Fluor 700 (clone 53-6.7;
eBioscience), CD4-PerCP (clone RM4-5; BD), IFN-c-PE (clone
XMG1.2; BD), CD45-FITC (clone 30-F11; BD) and CD107a/b-
Alexa Fluor 647 (clone 1D4B; eBioscience) were used. For
intracellular IFN-c staining, Cytofix/Cytoperm kit (BD) was used.
Generation of epitope-specific CD8+ T-cell clones
Isolated islets from prediabetic NOD mice were cultured for 7 d
in the presence of 50 U/ml recombinant human IL-2.
Figure 5. Islet-infiltrating CD8+ T-cells responding to contaminated PIA7-21 peptide are IGRP206-214-specific. Parallel IFN-c and Kd TMr
staining after stimulation with contaminated PIA7-21 or IGRP206-214 peptide. (A) Stimulation with contaminated PIA7-21 peptide and NRP-V7 K
d TMr
staining. (B) Stimulation with IGRP206-214 peptide and NRP-V7 K
d TMr staining. (C) Stimulation with contaminated PIA7-21 peptide and TUM K
d TMr
negative control staining. (D) Stimulation with peptide diluent alone and NRP-V7 Kd TMr staining.
doi:10.1371/journal.pone.0028866.g005
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Restimulation. On the 7th day of culture, 8–10 irradiated
(2,500 rad) islets/well from NOD-RIPB7 (F1) mice were added
and cultured for 7 d in the presence of 50 U/ml IL-2. Fresh IL-2
(50 U/ml final concentration) was added every 3 d. Fresh medium
was added when needed (every 7 d throughout the cloning).
Fourteen days after the addition of NOD-RIPB7 islets, another
restimulation was performed in the same way.
Sorting of epitope-specific CD8+ T cells. 14 d after the
second restimulation, recovered cells were stained with CD107a/
b in the presence of 10 mM peptide and 0.7 mM monensin
(Sigma) for 5 h at 37uC. One hundred CD8+CD107a/b+ cells/
well were sorted in 96-well V-bottom plates containing 10 fresh
irradiated islets from NOD-RIPB7 mice as feeders. IL-2 (50 U/
ml) was added and replenished every 3 d at the same final
Figure 6. CD8+ T-cell clones raised against contaminated PIA7-21 peptide are IGRP206-214-specific. (A) Schematic of the T-cell expansion
and cloning technique. (B) Sorting of epitope-reactive CD8+ T cells based on CD107a/b upregulation after in vitro peptide recall. Left plot shows
negative control (no stimulation); right plot shows CD107a/b staining after stimulation with contaminated PIA7-21 peptide. (C) Representative TMr
staining of one of the 3 T-cell clones generated. Staining for NRP-V7, PIB15-23 and negative control TUM K
d TMr is shown from left to right.
doi:10.1371/journal.pone.0028866.g006
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concentration. Fresh medium was added approximately every
7 d.
Restimulation. The first round of restimulation was
performed as before. For the second round, cells were
transferred to 96-well flat-bottom plates and the number of
feeder islets increased to 20/well.
Single-cell sorting. 14 d after the second restimulation, one
viable [7-aminoactinomycin D (7AAD)-negative] cell was sorted in
each well of a 96-well V-bottom plate, containing 10 NOD-RIPB7
islets/well. IL-2 was added as before and restimulation repeated
once as before until noticeable growth.
Nanochromatography
Peptide solutions (5 ml, 10 mM) were diluted 1:200 in 10%
acetonitrile (ACN; Carlo Erba), 0.1% trifluoroacetic acid (TFA;
Pierce). These preparations were either directly analysed by
matrix-assisted laser desorption/ionisation (MALDI) MS as
described below or separated and concentrated by reverse phase
nanochromatography as follows. Ten microliters of diluted
peptides were injected and separated with an Ultimate 3000 series
HPLC (Dionex). Injected peptides were trapped using solvent A
(0.1% TFA, 2% ACN) at 30 ml/min loading flow for 3 min in a
C18 trap column (Acclaim reverse phase C18 pepmap 100 phase,
5 mm particles, 100 A˚ pores, 5 mm length, 300 mm internal
diameter). The microvalve then oriented the elution to back flow
(300 nl/min) the peptides towards the analytical column (C18
pepmap 100, 3 mm particle, 100 A˚ pores, 15 cm length, 75 mm
i.d.) with a gradient rising from 10% solvent B (80% ACN, 20%
solvent A) at microvalve switch to 60% B in 34 min. Fractions
(20 s/each, i.e. 100 nl) were deposited in 96 wells of a 384-well
plate using a Probot fraction collector (Dionex). In order to
increase the concentration of collected peptides in each well, the
injection/fractionation was repeated 20 times and collected in the
same 96 plate positions to accumulate identical fractions. Fractions
were subsequently dehydrated in a speed vacuum concentrator
(Eppendorf). After solubilization in 5 ml 10% ACN 0.1% TFA,
each well represented a 10-fold concentration factor of the initial
peptide solution. Half microliter of each fraction was deposited on
a MALDI target to perform MS analysis.
The initial peptide dilution or the concentrated fractions were
mixed 1:1 on a MALDI target plate with 1 ml of 5 mg/ml of a-
cyano-4-hydroxycinnamic acid (CHCA) matrix (Laser Biolabs) in
70% ACN 0.1% TFA and 60 nM Glu-fibrinopeptide (Sigma) as
internal standard and analysed using a 4800 MALDI time-of-flight
(TOF) TOF analyser (ABSciex).
MS
Spectra acquisition and processing were performed using the
4000 series explorer software (ABSciex) version 3.5.28193 build
1011 in positive reflectron mode at fixed laser fluency with low
mass gate and delayed extraction. External plate calibration was
performed using 4 calibration spots at each corner of the plate.
Additional internal calibration was performed using Glu-fibrino-
peptide (m/z 1570.677). For each acquisition, 10 increments of 50
spectra in the range of m/z 600 to 4500 were acquired at a
200 Hz laser shot frequency. Five-hundred MS spectra per sample
were summed and processed to obtain monoisotopic values from
isotope clusters with a raw spectra s/n ratio of 20.
MS/MS
In each MS spectrum, the 12 most abundant peaks were
selected for fragmentation, starting with the least abundant. A cut-
off was applied at a minimum s/n of 20. Neighboring precursors
within 200 resolution were excluded. 1000 MS/MS spectra per
precursor were summed by increments of 50. Processing included
baseline subtraction and Stavitsky Golay smoothing with 3 points
across peak and a polynomial order of 4. Generated peaklists
reflected monoisotopic values from isotope clusters with a
minimum s/n ratio of 22.
Peptide identification
Peak lists were submitted to an in-house mascot (Matrix science)
version 2.2 search engine [23]. The Swiss-Prot database release
2010_05 (516603 sequences; 181919312 residues) was used with
restriction to mammalia (60,000 sequences). No enzymes were
selected as cleavage specificity. Parent and fragment mass
tolerances were respectively set to 50 ppm and 0.3 Da; variable
modification (oxidation) of methionines was allowed. A filter was
applied to the search in order to reduce false positives and
matching redundancies of the same peptide in several hits. All
matches above 5% risks of random matching were eliminated
(p,0.05). Peptide lists only included proteins matching the same
set of peptide and, if shared subsets were present, at least one non-
shared peptide was required. The minimal peptide score was 25.
With these parameters, the minimal protein score was 50.
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